Neuromod Devices Limited (“Neuromod”), an Irish medical technology company specialising in non-invasive neuromodulation technologies, has announced that Christopher M Smith became Strategic Advisor to the Board on June 8, and will join the company’s Board of Directors from January 3 2019.
Smith comes to Neuromod’s Board with an exemplary track record of leadership in the hearing and medical devices sectors. In January 2018, after 14 years with the company, Mr. Smith retired from his role as Chief Executive Officer and Director of Cochlear Ltd (COH.ASX), the global leader in cochlear implantation technology. During his time at the helm of Cochlear, Mr. Smith oversaw a period of substantial growth reaching annual sales in excess of AU$ 1 billion dollars and the market cap of the company grow to AU$ 10 billion (US$ 7.5 billion).
Manus Rogan, Chair of the Board of Neuromod commented, “We are delighted to welcome Chris to the Company. Neuromod will benefit from his track record guiding companies through rapid growth in the medical device and hearing sectors.”
Prior to Cochlear, Mr. Smith held roles as CEO in Residence with Warburg Pincus and as Group President of Gyrus Group in Reading, England, a market leader in surgical products. Mr Smith has previously served on the board of directors of publicly-listed Xtent Inc. as well as Startek Inc, Universal Biosensors, Gyrus Group Plc, and notably Acclarent Inc., a private ENT-focused medical device company that was acquired by Johnson & Johnson. Mr. Smith holds a BS from Texas A&M University.
Welcoming the appointment, Ross O’Neill, CEO of Neuromod said: “Chris is a recognised global leader in the hearing industry who is joining us at an exciting point in Neuromod’s evolution. We expect to conclude the second phase of the TENT-A clinical trial later this year and are excited to convert the promise of clinical data into a meaningful therapeutic option for the many patients with tinnitus anxiously awaiting effective, safe and convenient treatments. I look forward to working with Chris to bring this important intervention to market.”